# Phase 4 Master Protocol for Patients Prescribed Prademagene Zamikeracel for the Treatment of Wounds

> **NCT07717736** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Abeona Therapeutics, Inc** · enrollment: 100 (estimated)

## Conditions studied

- Epidermolysis Bullosa (EB)
- Recessive Dystrophic Epidermolysis Bullosa (RDEB)
- Dystrophic Epidermolysis Bullosa (DEB)

## Interventions

- **BIOLOGICAL:** Non-conforming pz-cel surgical application to RDEB wounds
- **PROCEDURE:** Additional biopsies
- **BIOLOGICAL:** Pz-cel surgical application to DEB wounds

## Key facts

- **NCT ID:** NCT07717736
- **Lead sponsor:** Abeona Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11
- **Primary completion:** 2031-11
- **Final completion:** 2032-07
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07717736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07717736, "Phase 4 Master Protocol for Patients Prescribed Prademagene Zamikeracel for the Treatment of Wounds". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07717736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*